Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $107.50 Average Target Price from Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been given a consensus rating of “Hold” by the twenty-two ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $107.50.

A number of research firms have issued reports on ZBH. JPMorgan Chase & Co. restated a “neutral” rating and issued a $100.00 target price (down from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Canaccord Genuity Group cut their price objective on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, UBS Group cut their price target on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a report on Thursday, November 6th.

Zimmer Biomet Stock Up 0.9%

Shares of NYSE ZBH opened at $90.23 on Friday. The firm’s 50-day moving average is $94.30 and its two-hundred day moving average is $96.58. The company has a market capitalization of $17.88 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 2.37 and a beta of 0.61. Zimmer Biomet has a 12-month low of $85.33 and a 12-month high of $114.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Institutional Trading of Zimmer Biomet

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Key Financial Inc lifted its holdings in shares of Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. increased its position in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its position in Zimmer Biomet by 83.7% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares during the last quarter. Root Financial Partners LLC purchased a new position in Zimmer Biomet during the third quarter worth approximately $31,000. Finally, Mather Group LLC. acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at $36,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.